Federated Hermes
KLRS

Federated Hermes’s Kalaris Therapeutics KLRS Stock Holding History

Federated Hermes’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-34
Closed -$196 – 2214
2026
Q1 		$196 Buy
+34
New +$302 ﹤0.01% 2041
2025
Q4 		– Sell
-578
Closed -$3.34K – 2251
2025
Q3 		$3.34K Sell
578
-56
-9% -$185 ﹤0.01% 1979
2025
Q2 		$1.69K Hold
634
– – ﹤0.01% 1966
2025
Q1 		$5.09K Buy
634
+59
+10% +$578 ﹤0.01% 1873
2024
Q4 		$5.55K Hold
575
– – ﹤0.01% 1889
2024
Q3 		$10.7K Sell
575
-87
-13% -$1.52K ﹤0.01% 1803
2024
Q2 		$11K Buy
662
+1
+0.2% +$18 ﹤0.01% 1769
2024
Q1 		$11.5K Buy
661
+576
+678% +$9.4K ﹤0.01% 1766
2023
Q4 		$1.34K Buy
+85
New +$3.35K ﹤0.01% 1956
2022
Q3 		– Sell
-6
Closed -$1K – 2258
2022
Q2 		$1K Sell
6
-5,532
-100% -$580K ﹤0.01% 2100
2022
Q1 		$860K Buy
+5,538
New +$1.1M ﹤0.01% 1298

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Federated Hermes's KLRS Position: Q2 2026 in Review

Federated Hermes sold out of Kalaris Therapeutics (KLRS) in Q2 2026, closing a stake of 34 shares — an estimated $196 sold.

Federated Hermes first reported a position in KLRS in Q1 2022 and held it in 11 quarters. The position peaked at $860K in Q1 2022. 56 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Federated Hermes reported no remaining Kalaris Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Federated Hermes sold 34 Kalaris Therapeutics shares in Q2 2026, an estimated $196.
  • Federated Hermes first reported a position in Kalaris Therapeutics in Q1 2022 and held it in 11 quarters.
  • Federated Hermes's Kalaris Therapeutics position peaked at $860K in Q1 2022.
  • 56 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Federated Hermes's 13F filing for Q2 2026, filed 12 Aug 2026.